{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:30:34Z","timestamp":1792740634976,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:00:00Z","timestamp":1650240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Vaccine clinical trials have been essential to developing effective severe acute respiratory syndrome coronavirus 2 vaccines. The challenges of supply chain disruptions, infection control, study designs, and participant factors that affect trial procedures are reviewed, with specific solutions to streamline the clinical trial process.<\/jats:p>","DOI":"10.1093\/cid\/ciac301","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:18:09Z","timestamp":1649935089000},"page":"S5-S10","source":"Crossref","is-referenced-by-count":2,"title":["Coronavirus Disease 2019 Vaccine Trials (and Tribulations): How to Improve the Process of Clinical Trials in a Pandemic"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6075-3990","authenticated-orcid":false,"given":"Amy C","family":"Sherman","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Precision Vaccines Program, Division of Infectious Diseases, Boston Children\u2019s Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Rouphael","sequence":"additional","affiliation":[{"name":"Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,18]]},"reference":[{"key":"2022081503564553500_ciac301-B1","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Global Health"},{"key":"2022081503564553500_ciac301-B2","doi-asserted-by":"crossref","first-page":"e57755","DOI":"10.1371\/journal.pone.0057755","article-title":"Risk in vaccine research and development quantified","volume":"8","author":"Pronker","year":"2013","journal-title":"PLoS One"},{"key":"2022081503564553500_ciac301-B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2022081503564553500_ciac301-B4","volume-title":"Comirnaty and Pfizer-BioNTech COVID-19 vaccine","author":"FDA","year":"2022"},{"key":"2022081503564553500_ciac301-B5","volume-title":"Janssen COVID-19 vaccine","author":"FDA","year":"2022"},{"key":"2022081503564553500_ciac301-B6","volume-title":"Spikevax and Moderna COVID-19 vaccine","author":"FDA","year":"2022"},{"key":"2022081503564553500_ciac301-B7","volume-title":"The U.S. COVID-19 vaccination program at one year: how many deaths and hospitalizations were averted?"},{"key":"2022081503564553500_ciac301-B8","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.vaccine.2020.04.039","article-title":"Extraordinary diseases require extraordinary solutions","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"2022081503564553500_ciac301-B9","doi-asserted-by":"crossref","first-page":"106263","DOI":"10.1016\/j.ypmed.2020.106263","article-title":"Contributing factors to personal protective equipment shortages during the COVID-19 pandemic","volume":"141","author":"Cohen","year":"2020","journal-title":"Prev Med"},{"key":"2022081503564553500_ciac301-B10","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"2022081503564553500_ciac301-B11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cct.2010.12.003","article-title":"More than the money: a review of the literature examining healthy volunteer motivations","volume":"32","author":"Stunkel","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"2022081503564553500_ciac301-B12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/08989621.2020.1782203","article-title":"An alarming retraction rate for scientific publications on coronavirus disease 2019 (COVID-19)","volume":"28","author":"Yeo-Teh","year":"2021","journal-title":"Account Res"},{"key":"2022081503564553500_ciac301-B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/QAI.0000000000002570","article-title":"COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black Americans living with HIV","volume":"86","author":"Bogart","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022081503564553500_ciac301-B14","doi-asserted-by":"crossref","first-page":"e2111629","DOI":"10.1001\/jamanetworkopen.2021.11629","article-title":"Factors associated with racial\/ethnic group\u2013based medical mistrust and perspectives on COVID-19 vaccine trial participation and vaccine uptake in the US","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Network Open"},{"key":"2022081503564553500_ciac301-B15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"key":"2022081503564553500_ciac301-B16","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1056\/NEJMp2033538","article-title":"Placebo-controlled trials of Covid-19 vaccines\u2014why we still need them","volume":"384","author":"Krause","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081503564553500_ciac301-B17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1126\/science.abc5312","article-title":"A strategic approach to COVID-19 vaccine R&D","volume":"368","author":"Corey","year":"2020","journal-title":"Science"},{"key":"2022081503564553500_ciac301-B18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMp2106970","article-title":"SARS-CoV-2 human challenge studies\u2014establishing the model during an evolving pandemic","volume":"385","author":"Rapeport","year":"2021","journal-title":"N Engl J Med"},{"key":"2022081503564553500_ciac301-B19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cll.2021.10.008","article-title":"Vaccine-induced severe acute respiratory syndrome coronavirus 2 antibody response and the path to accelerating development (determining a correlate of protection)","volume":"42","author":"Sherman","year":"2022","journal-title":"Clin Lab Med"},{"key":"2022081503564553500_ciac301-B20","volume-title":"Emergency Use Authorization","author":"FDA","year":"2022."},{"key":"2022081503564553500_ciac301-B21","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/cid\/ciab880","article-title":"Therapeutic emergency use authorizations (EUAs) during pandemics: double-edged swords","volume":"74","author":"Bhimraj","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2022081503564553500_ciac301-B22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2105\/AJPH.2020.306036","article-title":"Communicating effectively about emergency use authorization and vaccines in the COVID-19 pandemic","volume":"111","author":"Quinn","year":"2021","journal-title":"Am J Public Health"},{"key":"2022081503564553500_ciac301-B23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cct.2015.07.007","article-title":"Using e-technologies in clinical trials","volume":"45","author":"Rosa","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"2022081503564553500_ciac301-B24","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.695807","article-title":"SARS-CoV-2 mRNA vaccine attitudes as expressed in U.S. FDA public commentary: need for a public-private partnership in a learning immunization system","volume":"9","author":"Weitzman","year":"2021","journal-title":"Front Public Health"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac301\/43391719\/ciac301.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S5\/45407486\/ciac301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/Supplement_1\/S5\/45407486\/ciac301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T03:57:13Z","timestamp":1660535833000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/Supplement_1\/S5\/6569988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,18]]},"references-count":24,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2022,4,18]]},"published-print":{"date-parts":[[2022,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac301","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,15]]},"published":{"date-parts":[[2022,4,18]]}}}